Kyntra Bio (KYNB) and The Competition Financial Contrast

Kyntra Bio (NASDAQ:KYNB) is one of 457 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Kyntra Bio to related companies based on the strength of its analyst recommendations, risk, earnings, valuation, profitability, institutional ownership and dividends.

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 39.3% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 2.0% of Kyntra Bio shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Kyntra Bio and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	1	0	0	1.50
Kyntra Bio Competitors	4892	9963	15988	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 132.20%. Given Kyntra Bio’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio has less favorable growth aspects than its rivals.

Volatility & Risk

Kyntra Bio has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Kyntra Bio’s rivals have a beta of 5.46, suggesting that their average share price is 446% more volatile than the S&P 500.

Earnings & Valuation

This table compares Kyntra Bio and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyntra Bio	$29.62 million	-$47.58 million	0.14
Kyntra Bio Competitors	$430.98 million	-$67.98 million	-10.79

Kyntra Bio’s rivals have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Kyntra Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,598.55%	N/A	-26.27%
Kyntra Bio Competitors	-2,642.92%	-361.29%	-42.76%

Summary

Kyntra Bio rivals beat Kyntra Bio on 7 of the 13 factors compared.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.